REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
REGENXBIO Inc. (RGNX), a biopharmaceutical company incorporated in Delaware, filed this Current Report on Form 8-K on July 16, 2026. The filing discloses a significant capital raising event involving the sale of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 10,003,889 shares of Common Stock at $9.00 per share and pre-funded warrants to purchase 1,111,111 shares at $8.9999 per warrant.
- Over-Allotment: Underwriters exercised their option in full on July 17, 2026, to purchase an additional 1,667,250 shares of Common Stock.
- Net Proceeds: Approximately $107.8 million, after deducting underwriting discounts, commissions, and estimated offering expenses.
- Closing Date: Expected to close on July 20, 2026.
- Underwriters: Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Leerink Partners LLC, and Mizuho Securities USA LLC.
Material Changes and Unusual Items
This filing represents a material change in the company's capital structure due to the issuance of new equity securities. The transaction was executed pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291816). The filing does not provide comparative financial metrics such as revenue, profit, or cash flow for the period, as it is a current report focused on a specific corporate event rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary regarding future operational performance. The primary risk disclosed relates to the dilution of existing shareholders resulting from the issuance of new shares and pre-funded warrants. The pre-funded warrants do not carry voting rights until exercised.
Key Facts for Investor Verification
- Verify the final closing date of the offering (expected July 20, 2026) and the actual net proceeds received.
- Confirm the total number of shares outstanding post-offering to assess dilution impact.
- Review the attached press release (Exhibit 99.1) for management's stated use of proceeds.
- Monitor the exercise of pre-funded warrants, which are exercisable immediately and do not expire.